PROVENTION BIO, INC. SELECTED FINANCIAL DATA (unaudited) (in thousands, except per share data) | ||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||
2018 | 2017 | 2018 | 2017 | |||||||||
Statement of Operations Data: | ||||||||||||
Operating expenses: | ||||||||||||
Research and development | $ | 4,140 | $ | 887 | $ | 17,684 | $ | 4,618 | ||||
General and administrative | 1,272 | 488 | 2,929 | 788 | ||||||||
Total operating expenses | 5,412 | 1,375 | 20,613 | 5,406 | ||||||||
Operating loss | (5,412) | (1,375) | (20,613) | (5,406) | ||||||||
Other income (expense): | ||||||||||||
Interest income | 237 | 50 | 339 | 80 | ||||||||
Change in fair value of warrant liability | (217) | (37) | (520) | (123) | ||||||||
Net loss | (5,392) | (1,362) | (20,794) | (5,449) | ||||||||
Accretion on Series A Convertible Redeemable Preferred Stock | (25) | (127) | (276) | (217) | ||||||||
Net loss attributable to common stockholders | $ | (5,417) | $ | (1,489) | $ | (21,070) | $ | (5,666) | ||||
Net loss per common share, basic and diluted | $ | (0.17) | $ | (0.15) | $ | (1.21) | $ | (0.62) | ||||
Weighted average common shares outstanding, basic and diluted | 32,000 | 10,000 | 17,414 | 9,158 | ||||||||
September 30, 2018 | December 31, 2017 | |||||||||||
Balance Sheet Data: | ||||||||||||
Cash and cash equivalents | $ | 64,297 | $ | 21,834 | ||||||||
Total assets | $ | 66,322 | $ | 22,428 | ||||||||
Total liabilities | $ | 1,234 | $ | 2,276 | ||||||||
Series A Convertible Redeemable Preferred Stock | $ | - | $ | 26,185 | ||||||||
Accumulated deficit | $ | (30,092) | $ | (9,298) | ||||||||
Total stockholders' equity (deficit) | $ | 65,088 | $ | (6,033) | ||||||||
